RFCA
RGLS icon

R&F Capital Advisors’s Regulus Therapeutics RGLS Stock Holding History

R&F Capital Advisors’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-260
Closed -$70K – 801
2016
Q4 		$70K Buy
+260
New +$84.5K 0.02% 463

Other funds holding RGLS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
SDIC
South Dakota Investment Council Sioux Falls, South Dakota $5.84B AUM 30.42% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

R&F Capital Advisors's RGLS Position: Q1 2017 in Review

R&F Capital Advisors sold out of Regulus Therapeutics (RGLS) in Q1 2017, closing a stake of 260 shares — an estimated $70K sold.

R&F Capital Advisors first reported a position in RGLS in Q4 2016 and held it in 1 quarter. The position peaked at $70K in Q4 2016. 58 funds tracked by Wall St. Rank hold RGLS as of Q1 2017.

  • R&F Capital Advisors reported no remaining Regulus Therapeutics position as of Q1 2017 after selling out during the quarter.
  • R&F Capital Advisors sold 260 Regulus Therapeutics shares in Q1 2017, an estimated $70K.
  • R&F Capital Advisors first reported a position in Regulus Therapeutics in Q4 2016 and held it in 1 quarter.
  • R&F Capital Advisors's Regulus Therapeutics position peaked at $70K in Q4 2016.
  • 58 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q1 2017.

Based on R&F Capital Advisors's 13F filing for Q1 2017, filed 15 May 2017.